STAGE III PANCREATIC CANCER AJCC V8
Clinical trials for STAGE III PANCREATIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III PANCREATIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III PANCREATIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-stage trial tests a new targeted drug (CA-4948) added to standard chemotherapy for people with advanced pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink or stabilize the cancer. About 43 ad…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New drug cocktail shows promise in halting pancreatic cancer
Disease control OngoingThis study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help keep advanced pancreatic cancer from getting worse in people whose cancer cannot be removed by surgery. About 28 adults who have already responded to initial treatment will receive these d…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug cocktail aims to starve pancreatic tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see how well the drugs work together to starve cancer cells by cutting off a…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New cocktail aims to outsmart pancreatic cancer
Disease control OngoingThis early-phase trial tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The study combines a targeted therapy (anetumab ravtansine) with immunotherapy drugs (nivolumab, ipilimumab) and chemotherapy (gemcitabine) to s…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Could a common blood pressure drug boost radiation against tough pancreatic tumors?
Disease control OngoingThis early-phase study tests whether adding the blood pressure drug losartan to a shorter, stronger course of radiation can help treat pancreatic cancer that is either hard to remove surgically or has spread nearby. Losartan may improve blood flow and oxygen in the tumor, making …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Sound waves boost chemo in tough pancreatic cancer trial
Disease control OngoingThis study tests a technique called sonoporation, which uses ultrasound and tiny bubbles to help chemotherapy drugs get into cancer cells more effectively. It includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already scheduled for standard chemotherapy…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Flemming Forsberg • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Experimental pancreatic cancer combo trial halted midway
Disease control TerminatedThis early-stage study tests a new drug called NBTXR3, which is activated by radiation, for people with pancreatic cancer that is locally advanced or borderline resectable. The goal is to find a safe dose and see if it helps control the tumor. The trial was suspended and enrolled…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Switching chemo Mid-Treatment shows promise for tough pancreatic cancers
Disease control OngoingThis study tests whether switching from one chemotherapy combination to another before surgery can help people with pancreatic cancer that can be removed or has spread nearby. About 42 adults with specific stages of pancreatic cancer will receive either FOLFIRINOX or gemcitabine/…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Tablet-Based exercise program aims to boost strength in pancreatic cancer patients
Symptom relief OngoingThis study tests whether a supervised, at-home resistance training program using a tablet is safe and helpful for people with advanced pancreatic cancer or those recovering from surgery. About 25 participants will do guided exercises while on chemotherapy or after surgery. The go…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 04, 2026 16:20 UTC